New Zealand consults on Victrelis listing and some Pegasys amendments

19 July 2013

New Zealand’s Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir (Victrelis) as a result of a provisional agreement with Merck Sharp and Dohme (New Zealand), the local unit of US pharma giant Merck & Co (NYSE: MRK) and to amend the listing of pegylated interferon with/without ribavirin (Pegasys and Pegasys RBV Combination Pack) as a result of a provisional agreement with the local subsidiary of Swiss pharma major Roche (ROG: SIX).

The provisional agreements were reached as a result of a Request for Proposals issued by PHARMAC on 30 April 2013. In summary, this proposal would result in:

• boceprevir (Victrelis) being funded, under Special Authority, from September 1, 2013 for treatment of patients living with chronic hepatitis C;
• with IL-28 gene CT or TT allele; and
• who have previously been treated with pegylated interferon and ribavirin who were partial responders, responder relapsers or were treated prior to 2005;
• Victrelis being the only funded protease inhibitor for the treatment of hepatitis C in the community until June 30, 2016;
• the funded access criteria for pegylated interferon with/without ribavirin being widened from September 1, 2013, to cover retreatment of patients living with chronic hepatitis C who have previously been treated with pegylated interferon and ribavirin who were partial responders, responder relapsers or were treated prior to 2005 in combination with boceprevir; and
• Pegasys being the only funded brand of pegylated interferon with/without ribavirin in the community until June 30, 2017.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology